RhumbLine Advisers’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,125
| Closed | -$3.38K | – | 4312 |
|
|
2024
Q2 | $3.38K | Sell |
1,125
-49
| -4% | -$147 | ﹤0.01% | 4140 |
|
|
2024
Q1 | $5.46K | Hold |
1,174
| – | – | ﹤0.01% | 3972 |
|
|
2023
Q4 | $4.86K | Hold |
1,174
| – | – | ﹤0.01% | 3988 |
|
|
2023
Q3 | $3.52K | Sell |
1,174
-2,274
| -66% | -$6.82K | ﹤0.01% | 4037 |
|
|
2023
Q2 | $8.48K | Sell |
3,448
-34,187
| -91% | -$84.1K | ﹤0.01% | 3984 |
|
|
2023
Q1 | $85K | Buy |
37,635
+1,092
| +3% | +$2.47K | ﹤0.01% | 2876 |
|
|
2022
Q4 | $128K | Buy |
36,543
+280
| +0.8% | +$981 | ﹤0.01% | 2871 |
|
|
2022
Q3 | $1.34M | Buy |
36,263
+2,828
| +8% | +$105K | ﹤0.01% | 1986 |
|
|
2022
Q2 | $635K | Buy |
33,435
+11,876
| +55% | +$226K | ﹤0.01% | 2365 |
|
|
2022
Q1 | $582K | Buy |
21,559
+5,975
| +38% | +$161K | ﹤0.01% | 2354 |
|
|
2021
Q4 | $351K | Sell |
15,584
-242
| -2% | -$5.45K | ﹤0.01% | 2658 |
|
|
2021
Q3 | $415K | Buy |
15,826
+673
| +4% | +$17.6K | ﹤0.01% | 2630 |
|
|
2021
Q2 | $485K | Sell |
15,153
-1,240
| -8% | -$39.7K | ﹤0.01% | 2579 |
|
|
2021
Q1 | $577K | Sell |
16,393
-735
| -4% | -$25.9K | ﹤0.01% | 2420 |
|
|
2020
Q4 | $549K | Buy |
17,128
+1,130
| +7% | +$36.2K | ﹤0.01% | 2403 |
|
|
2020
Q3 | $602K | Sell |
15,998
-1,845
| -10% | -$69.4K | ﹤0.01% | 2198 |
|
|
2020
Q2 | $798K | Buy |
+17,843
| New | +$798K | ﹤0.01% | 2136 |
|